{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-013165","form_type":"8-K","ticker":"CLSDQ","cik":"0001539029","company_name":"Clearside Biomedical, Inc.","filed_at":"2023-04-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.325661+00:00","generated_at":"2026-06-17T00:42:49.946941+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Clearside Biomedical announces plans for Phase 2b ODYSSEY trial of CLS-AX in wet AMD","bullets":["Phase 2b trial ODYSSEY to enroll 60 patients with wet AMD; 2:1 randomization CLS-AX vs aflibercept.","Primary outcome: mean change in BCVA from baseline to Week 36; secondary include CST and treatment burden.","CLS-AX arm: 3 aflibercept loading doses + CLS-AX at baseline, then at least every 24 weeks.","Enrollment starts Q2 2023; topline results expected in Q3 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-013165","json":"https://secwatch.observer/filing/0000950170-23-013165.json","markdown":"https://secwatch.observer/filing/0000950170-23-013165.md","text":"https://secwatch.observer/filing/0000950170-23-013165.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1539029/000095017023013165/0000950170-23-013165-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1539029/000095017023013165/clsd-20230418.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T00:42:49.946941+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}